spacer
home > ict > autumn 2019 > the formula for success
PUBLICATIONS
International Clinical Trials

The Formula for Success





In early 2019, the FDA released a revised draft guidance for rare disease clinical trials (1). The guidance, updated from a 2015 version, provided clarification in certain areas such as natural history studies, evaluation and validation of biomarkers as surrogate endpoints, evaluation of novel drug compounds, drug manufacturing, and safety. Well-received, the 2019 guidance is intended to encourage sponsors to tackle the complex issues associated with rare disease research proactively so that research can be conducted more effectively and efficiently.

Main Challenges

Rare diseases affect a small population of people who are dispersed across the world, and it makes country and site selection, clinical trial recruitment, and long-term retention particularly complex. Furthermore, many rare diseases are difficult to diagnose, and, as a result, a misdiagnosis can occur. Although more rare diseases are being identified through recent medical advancements and development of new diagnostic techniques, it typically takes time for the diagnostic and screening standards to be established. Obtaining an accurate diagnosis is often one of the first obstacles to overcome.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
5
     

There are no comments in regards to this article.

spacer
About the authors


Dr Pavle Vukojevic, Chief Medical Officer, joined Pharm-Olam in 1997 and supports clinical operations with protocol development, therapeutic training, patient safety issues, study management, and feasibility support. Pavle received his MD in 1988 from the University of Belgrade, Serbia, and also has a Master’s degree in Immunology and a specialisation in Internal Medicine. He is a former President of the Association of Clinical Research Professional’s Serbia Chapter and was an assistant professor at the Medical School University of Belgrade for internal medicine/ rheumatology. He is the author of ‘Conducting Clinical Trials in Europe: An Insider’s Analysis’, written for Insight Pharma Reports.

Dr Milan Marinkov has been with Pharm- Olam since 2013 and is currently Senior Medical Director. Milan is the leading medic and head of the Rare and Orphan Disease Center of Excellence, responsible for the evaluation, medical management, and conduct of multiple global studies within the rare disease study portfolio. He received his medical degree from the University of Novi Sad, Serbia, and is currently engaged in PhD studies.

Dr Jovana Vlajkovic-Josic, project management professional, joined Pharm-Olam in 2004 and is currently Associate Medical Director with experience in both medical and project management departments. As a licensed physician with postgraduate immunology training, Jovana’s orphan clinical trial experience includes a broad range of indications and phases.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avantor to Acquire Masterflex; Expands Proprietary Single-Use Offering for Bioproduction

RADNOR, Pa., Sept. 7, 2021 /PRNewswire/ – Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials industries, today announced that it has entered into a definitive agreement to acquire the Masterflex bioprocessing business and related assets (collectively "Masterflex") of Antylia Scientific.
More info >>

White Papers

Transforming Temperature Data Management Practices to Reduce Labor Costs and Improve Visibility and Control

Berlinger & Co AG

There are a number of temperature monitoring database options available to the biopharma supply chain professional and choosing the right one can significantly improve workflow which will reduce administrative time. This article will provide insight into practices for improving common processes through enhanced database functionality in the areas of managing data loggers by expiry date, storing and retrieving calibration certificates and acknowledging/documenting common temperature excursion events. Additionally, it describes the unique features and benefits of the Berlinger Smartview® data management system. Smartview® is a “Software as a Service” (SaaS) platform designed to efficiently and accurately manage both workflow and data in a regulatory compliant manner (21 CRF Part 11 & Annex 11). This comprehensive temperature data management system ensures reliability, accuracy, security, accessibility, and visibility to supply chain professionals, enhancing Good Distribution Practices (GDP) of temperature sensitive shipments.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement